Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 3,709 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the transaction, the vice president now directly owns 17,500 shares in the company, valued at $791,525. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) traded up 3.05% during mid-day trading on Wednesday, hitting $45.65. 1,128,367 shares of the stock were exchanged. Supernus Pharmaceuticals, Inc. has a 52-week low of $17.25 and a 52-week high of $46.45. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of 23.03 and a beta of 1.31. The stock has a 50 day moving average of $42.54 and a 200-day moving average of $34.58.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current fiscal year.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/insider-selling-supernus-pharmaceuticals-inc-supn-vp-sells-3709-shares-of-stock/1496798.html.

A number of research analysts have issued reports on SUPN shares. Jefferies Group LLC set a $35.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 10th. Cowen and Company boosted their price objective on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, May 11th. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, May 11th. Piper Jaffray Companies raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $30.00 to $44.00 in a research report on Thursday, June 1st. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $48.43.

Institutional investors have recently made changes to their positions in the stock. Virginia Retirement Systems ET AL raised its position in shares of Supernus Pharmaceuticals by 17.1% in the first quarter. Virginia Retirement Systems ET AL now owns 71,800 shares of the specialty pharmaceutical company’s stock valued at $2,247,000 after buying an additional 10,500 shares in the last quarter. Turner Investments LLC purchased a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $219,000. Sheets Smith Wealth Management purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $378,000. Bank of America Corp DE raised its position in shares of Supernus Pharmaceuticals by 10.7% in the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock valued at $11,361,000 after buying an additional 35,069 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its position in shares of Supernus Pharmaceuticals by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the specialty pharmaceutical company’s stock valued at $639,000 after buying an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.